Heplisav-B is a recombinant hepatitis B vaccine approved by the U.S. FDA for adults 18 years and older. It uses a genetically engineered hepatitis B surface antigen and a novel adjuvant system to produce a stronger immune response than traditional vaccines.
Unlike older hepatitis B vaccines that require three doses over six months, Heplisav-B completes protection in just two doses administered one month apart. This shortened schedule improves adherence and reduces missed appointments, especially among high-risk populations.
The vaccine is manufactured by GSK and was approved in 2017 after clinical trials showed 98% efficacy in preventing hepatitis B infection in healthy adults. It is specifically designed for adults, not children or adolescents under 18.
Heplisav-B contains the hepatitis B surface antigen (HBsAg), which is produced using yeast cells (Saccharomyces cerevisiae) through recombinant DNA technology. This protein triggers the immune system to recognize and fight the actual virus if exposed later.
What sets Heplisav-B apart is its use of a proprietary adjuvant called CpG 1018. This synthetic molecule mimics bacterial DNA and activates toll-like receptor 9 (TLR9), enhancing the body's innate immune response. This leads to faster and stronger antibody production compared to older aluminum-based adjuvants.
In Phase III clinical trials, 98% of participants developed protective antibodies (anti-HBs ≥10 mIU/mL) after two doses. By comparison, older three-dose regimens achieved around 90% seroprotection in adults. The higher response rate makes Heplisav-B particularly effective in populations with weaker immune responses, such as people with diabetes or obesity.
The CDC recommends Hepatitis B vaccination for all adults aged 18 and older who have not previously been vaccinated or lack immunity. This includes individuals with risk factors such as:
Heplisav-B is preferred over older vaccines for adults due to its superior immunogenicity and simplified dosing. The two-dose regimen increases completion rates-studies show 96% of patients complete both doses, compared to 75% for the three-dose series.
For adults with chronic conditions, Heplisav-B is especially beneficial. A 2020 study published in Clinical Infectious Diseases found that people with type 2 diabetes had a 20% higher seroconversion rate with Heplisav-B than with Engerix-B (a standard three-dose vaccine).
Most side effects of Heplisav-B are mild and resolve within 1-2 days. The most frequently reported reactions include:
Severe allergic reactions are rare, occurring in fewer than 1 in 100,000 doses. The FDA monitors safety through the Vaccine Adverse Event Reporting System (VAERS), and no unexpected safety signals have emerged since approval.
A notable difference from older vaccines: Heplisav-B causes more frequent systemic symptoms because of its potent adjuvant. However, these are generally well-tolerated and do not lead to treatment discontinuation. In clinical trials, less than 2% of recipients stopped the series due to side effects.
Heplisav-B is not a treatment for existing hepatitis B infection. It cannot clear the virus from someone already infected. It is preventive only.
It is also not interchangeable with other hepatitis B vaccines. The two-dose schedule and unique adjuvant mean switching between brands may reduce effectiveness. The CDC advises completing the series with the same product.
One common misconception is that Heplisav-B is available for children. It is not. The vaccine was studied exclusively in adults. For pediatric use, other formulations like Recombivax HB remain standard.
In 2021, a primary care clinic in Chicago adopted Heplisav-B for all unvaccinated adult patients. Over 12 months, they enrolled 420 patients aged 18-65.
Patients received dose 1 during their initial visit. Dose 2 was scheduled one month later via automated reminder. Completion rate: 95%. Among those with diabetes, 97% developed protective antibodies.
By contrast, the clinic's previous three-dose program had a 72% completion rate. The shorter schedule reduced patient drop-off and improved population-level coverage.
| Vaccine | Dosing Schedule | Adjuvant | Seroconversion Rate (Adults) | Approved Age Group |
|---|---|---|---|---|
| Heplisav-B | 2 doses, 1 month apart | CpG 1018 (TLR9 agonist) | 98% | 18+ |
| Engerix-B | 3 doses, 0, 1, 6 months | Aluminum hydroxide | 90% | 18+ |
| Recombivax HB | 3 doses, 0, 1, 6 months | Aluminum hydroxide | 85-90% | 11-18 years and adults |
Source: FDA labeling, CDC Pink Book (2023), Clinical Infectious Diseases 2020;71(1):e1-e10.
Heplisav-B is a effective, two-dose hepatitis B vaccine for adults. Its enhanced immune response and simplified schedule make it ideal for improving vaccination rates in at-risk populations. It is not a cure, not for children, and not interchangeable with other vaccines. When used correctly, it prevents a serious liver disease that affects over 850,000 Americans annually.